Intrahepatic cholestasis of pregnancy

Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Medical specialties, Hepatology, Cholestatic pruritus, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Intrahepatic cholestasis of pregnancy, Liver disease, Ascending cholangitis

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.

Key Points: 
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS.
  • The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Hepatology, Cholestatic pruritus, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Intrahepatic cholestasis of pregnancy, Liver disease, Ascending cholangitis

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, June 10, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Hepatology, Cholestatic pruritus, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Intrahepatic cholestasis of pregnancy, Liver disease, Ascending cholangitis

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Medical specialties, Hepatology, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Liver disease, Ascending cholangitis, Intrahepatic cholestasis of pregnancy, Cholestatic pruritus

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Hepatology, Cholestatic pruritus, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Intrahepatic cholestasis of pregnancy, Liver disease, Ascending cholangitis

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences:

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences:
    The presentation will be available for viewing on Tuesday, March 9, 2021 at 7:00 a.m.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Hepatology, Cholestasis, Primary sclerosing cholangitis, Primary biliary cholangitis, Liver disease, Ascending cholangitis, Intrahepatic cholestasis of pregnancy, Cholestatic pruritus

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, January 8, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Hepatology, Cholestasis, Primary sclerosing cholangitis, Intrahepatic cholestasis of pregnancy

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 11, 2020
Biotechnology, Pharmaceutical, Health, Medical specialties, Hepatology, Cholestasis, Primary sclerosing cholangitis, Intrahepatic cholestasis of pregnancy

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The award is subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.

Mirum Pharmaceuticals Announces Virtual Investor Day 2020

Retrieved on: 
Monday, December 7, 2020
Biotechnology, Pharmaceutical, Health, Medical specialties, Hepatology, Digestive diseases, Clinical medicine, Progressive familial intrahepatic cholestasis, Cholestasis, Alagille syndrome, PFIC, Biliary atresia, Primary sclerosing cholangitis, Intrahepatic cholestasis of pregnancy, Liver

A replay of the webcast will be available in the Investor Relations section of Mirums website following the live event.

Key Points: 
  • A replay of the webcast will be available in the Investor Relations section of Mirums website following the live event.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia.
  • Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, November 11, 2020
Oncology, Health, Other Health, Managed care, General Health, Pharmaceutical, Biotechnology, Medical specialties, Hepatology, Cholestasis, Primary sclerosing cholangitis, Intrahepatic cholestasis of pregnancy

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The company is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy.